MARKET WIRE NEWS

Harrow: When Cheaper Doesn't Mean Attractive (Rating Upgrade)

Source: SeekingAlpha

2025-03-29 16:30:00 ET

Summary

  • Harrow's stock is down 17% since my last analysis and "Sell" recommendation.
  • Harrow's Q4 and FY24 results show significant revenue growth and improved net income, but the company faces complex reimbursement challenges and tough competition.
  • Valuation models suggest Harrow is fairly valued if it achieves 20% revenue growth and 15% FCF margins, though these are lofty expectations.
  • I upgrade Harrow to "Hold" due to its solid earnings and more reasonable valuation, but remain cautious about its complex business structure and high growth targets.

Introduction

Harrow, Inc. ( HROW ) stock is down another 17% since my “ Sell ” recommendation in December....

Read the full article on Seeking Alpha

For further details see:

Harrow: When Cheaper Doesn't Mean Attractive (Rating Upgrade)
Harrow Health Inc. 8.625% senior notes due 2026

NASDAQ: HROWL

HROWL Trading

0.11% G/L:

$25.591 Last:

3,436 Volume:

$25.55 Open:

mwn-app Ad 300

HROWL Latest News

May 23, 2025 02:16:00 am
Long Term Trading Analysis for (HROWL)
February 28, 2025 12:14:00 am
Objective long/short (HROWL) Report
February 17, 2025 09:52:00 am
Where are the Opportunities in (HROWL)

HROWL Stock Data

$947,624,703
31,392,612
N/A
160
6427%
Pharmaceuticals
Healthcare
US
Nashville

Subscribe to Our Newsletter

Link Market Wire News to Your X Account

Download The Market Wire News App